Sichenzia Ross Ference Carmel LLP Represents AEON Biopharma in $20 Million Public Offering

New York, NY – January 6, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, in its $20 million public offering.

Aegis Capital Corp. acted as the sole book-running manager for the offering. The Aegis team was led by Isaac Eide, Anthony Lapadula and Dilnaman Singh Sachdeva.

The SRFC team was led by partner Ross Carmel and associate Jesse Blue.